糖皮质激素与COPD合并肺癌

Association between glucocorticoid and COPD combined with lung cancer

大气污染及吸烟是COPD的主要致病因素，目前发病率呈逐渐增高趋势，且居全球死亡原因的第4位，合并肺癌的也较常见。COPD合并肺癌患者存在不同的肺功能损伤，导致肺功能异常，细胞因子及炎症因子异常分泌及浓聚，因此糖皮质激素近年来被推荐用于COPD稳定期和急性加重期的治疗，同时也被发现在肺癌的预防治疗中可减轻放、化疗不良反应。为了探讨肺癌和COPD的相关性，我们就近年来肺癌和COPD在炎症反应方面所取得的进展进行回顾和综述，探讨糖皮质激素在肺癌治疗中的重要意义，以期在肺癌的临床诊疗工作中起到积极影响。

Lung cancer is one of the most dangerous malignant tumors which is viewed as a serious threat to people＇s health and life in the world. Chronic obstructive pulmonary diseases （COPD） combined with lung cancer is usually caused by atmospheric contamination and smoking and its morbidity is gradually raising. The damage of lung function appearing in the patients with COPD combined with lung cancer causes abnormal secretion and concentration of inflammatory factors. Glucocorticoid is recommended to treat COPD in recent years, at the same time it is found that it is important in the prevention of lung cancer. Glucocorticoid is also explored to release toxic reaction of chemoradiotherapy. To discuss the relevance between lung cancer and COPD, we review the advance in inflammation induced by COPD and lung cancer, and analyse the significance of glucocorticoid in the treatment of lung cancer, which have a meaningful effect on the diagnosis and treatment of lung cancer.